Portugal's Cancer Crisis: Why 30% of Residents Lack Prevention Knowledge and What It Costs Families

Portugal's leading cancer charity has marked 85 years of operations by warning that nearly one-third of the population remains dangerously uninformed about cancer prevention — a gap that experts say is costing lives and pushing treatment costs higher. The Liga Portuguesa Contra o Cancro (LPCC) supported more than 25,000 oncology patients in 2025, a 15% increase from the previous year, while direct aid spending reached €2.2M as families struggle with the financial fallout of diagnosis.

Why This Matters

• 30% of residents lack basic cancer awareness, limiting their ability to prevent or catch the disease early.

• 60% of cancers are preventable through lifestyle changes and early screening, according to LPCC data.

• Colorectal cancer screening participation stands at just 9% — one of the lowest rates in the European Union.

• Parliament rejected 100% sick pay for cancer patients in March 2026, leaving families to shoulder income losses of up to 45%.

The Information Gap Portugal Can't Afford

Vítor Veloso, president of the LPCC, told reporters that the country's approach to health literacy remains dangerously uneven. "We have around 30% of the population that is neither informed nor adequately sensitized. They lack education for health," he said, noting that his organization is practically the sole provider of national-level cancer literacy, with minimal state involvement in public awareness campaigns.

The state has not developed comprehensive dedicated funding for cancer education programs, leaving the LPCC — a nonprofit that receives no government subsidies — to shoulder the burden through donations, annual fundraising drives, and bequests. The charity engages roughly 400,000 secondary school students annually, hoping younger generations will transfer prevention knowledge to adults at home.

Yet the data reveal a troubling gender divide: while adolescent boys are drinking and smoking less, consumption among adolescent girls is rising, Veloso warned. This trend threatens to reverse decades of progress in lung cancer rates, which remain the leading cause of cancer death among men and the third among women in Portugal.

Screening Programs: Current Performance and Participation Gaps

Portugal operates three national cancer screening programs — for breast, cervical, and colorectal cancers — but participation rates reveal significant opportunities for improvement. The breast cancer screening program achieved over 90% population coverage in 2024, exceeding the 2030 target, but nearly half of women summoned for diagnostic mammography in 2022 did not attend.

Colorectal cancer, the most prevalent cancer in the country with roughly 10,000 new cases per year, faces challenges in screening uptake. Just 36.5% of eligible residents participated in 2022, and only 28% received an invitation in 2025. Portugal's 9% overall participation rate lags far behind EU averages, despite evidence that early detection allows for polyp removal before malignancy and significantly reduces mortality.

The cervical cancer screening program shows better results but still falls short of targets. In 2025, only 27% of eligible women received an invitation, though 86% of those invited completed the test. Coverage remains at 61%, below the 90% target for 2030.

Administrative and logistical factors in the screening invitation process contribute to delayed diagnoses that require complex and expensive treatments with lower success rates.

Lung and Prostate Screening on the Horizon

The Portugal Ministry of Health announced pilot programs for lung cancer screening in April 2026, funded by tobacco tax revenues. Low-dose computed tomography (LDCT) will target high-risk populations — smokers and former smokers aged 55 to 74 — in a bid to address a major health burden. Research shows LDCT screening can reduce mortality by 21% in at-risk groups, potentially preventing significant deaths in screened populations.

Pilot projects are launching in hospitals across northern and southern regions in the second half of 2026. Prostate and gastric cancer screening pilots are in the pipeline, though no firm dates have been set.

Veloso credits advances in immunotherapy for dramatic survival gains in lung cancer patients, noting that "it provides extraordinary survival in many lung cancers," even as the disease continues to challenge the health system. A new national platform announced in February 2026 aims to harmonize implementation, registration, monitoring, and evaluation of all screening programs under one roof.

The Economic Burden Families Bear Alone

Families facing an oncology diagnosis in Portugal confront an average monthly financial impact of €655, driven by lost income and rising expenses. The cost of cancer care remains substantial, with medicines representing a primary expense driver.

The Segurança Social pays sick leave subsidies ranging from 55% to 75% of reference income, depending on the duration of leave. For many households, that gap is unbridgeable. The LPCC distributed more than €2.2M in direct aid in 2025 — covering electricity, water, rent, transport, medication, and food — yet acknowledges it cannot reach all families in need.

In March 2026, Parliament rejected six opposition proposals to pay 100% sick leave to cancer patients, eliminate waiting periods, and remove time limits on benefit payments. The PSD and CDS-PP parties, supporting the government, voted against the measures, citing sustainability concerns and the need for a gradual, targeted approach. The Socialist Party (PS) abstained, arguing the issue should be addressed in the forthcoming revision of the Labor Code and the next State Budget.

Veloso confirmed the LPCC is preparing an economic impact study and plans to "return to the charge in the coming months," escalating its campaign for full income replacement during treatment.

What the LPCC Delivers — and Where It Struggles

The charity's 85th anniversary, marked by a ceremony at the Centro Cultural de Belém attended by Health Minister Ana Paula Martins, underscored both its achievements and the scale of unmet need.

In 2025, the LPCC provided:

• 21,300 free psycho-oncology consultations, supporting nearly 3,700 patients.

• 14,537 early detection consultations for skin and oral cancers, alongside smoking cessation and nutrition counseling.

• €700,000 in research and training funding, double the previous investment, supporting 38 research grants, four research centers, and training for 1,810 health professionals.

• Accompaniment for more than 8,200 patients in day centers and approximately 400 in residential care homes.

The organization relies on 21,700 volunteers to maintain proximity to patients and families, but the increasing incidence of cancer — projected to rise 12% by 2030 and 20% by 2040 — is stretching capacity. Veloso emphasizes that the LPCC must adapt to "a context of growing complexity," driven by longer lifespans, the interplay of lifestyle and genetics, rising infection rates, and improved diagnostic capability.

Impact on Residents and Expats

For anyone living in Portugal — citizens, long-term residents, or expats — the gaps in screening participation and financial support translate directly into higher personal risk and economic exposure. The low screening uptake means neighbors and colleagues are being diagnosed at later stages, when treatment is costlier and less likely to succeed.

Actionable steps:

• Request screening invitations directly from your primary care unit (unidade de saúde primários) if you have not received one. Eligibility: breast (ages 45–74, biennial), cervical (ages 25–60/65, regular), colorectal (ages 50–74, biennial fecal occult blood test).

• Apply for the Atestado Médico de Incapacidade Multiuso (AMIM) immediately upon diagnosis. Since 2024, newly diagnosed patients can obtain the AMIM directly at the hospital with an automatic 60% disability rating for five years, unlocking access to benefits.

• Contact the LPCC for direct aid if facing financial hardship. The organization provides support for utilities, rent, transport, medication, and food.

Maximum Waiting Times Remain a Bottleneck

Veloso identified compliance with maximum guaranteed response times as the greatest challenge facing cancer patients in Portugal. "In some types of cancer, one month can make the difference between a cure and poor quality of life," he said.

Portugal's performance on innovation access, however, compares favorably to peers. Despite criticism that the Infarmed regulatory agency is slow to approve new treatments, Veloso insists the country "is very much in the picture" relative to its budget. "We cannot speak too badly of Infarmed. It takes quite a while to release some innovations, but in any case, it is not among the worst in Europe."

When a treatment unavailable domestically is known to be effective, specialized Portuguese centers can transfer patients to European hospitals for care.

Taboo Fading, but Stigma Lingers

Veloso believes the cultural perception of cancer is shifting. "Cancer is increasingly seen as a chronic and curable disease. There are many weapons to fight it," he said, citing not only radiotherapy and surgery but, crucially, primary and secondary prevention.

Yet the "it only happens to others" mentality persists, particularly in underserved and rural areas. The LPCC's strategy of embedding health education in secondary schools aims to normalize prevention conversations early, but without broader state involvement, the reach remains limited.

The Road Ahead: Housing, Advocacy, and Representation

Looking forward, the LPCC plans to construct or renovate patient housing facilities from north to south, accommodating those who need to stay near hospitals for treatment but do not require inpatient care. The charity also intends to intensify its advocacy for fiscal benefits, gradual return-to-work programs, multiuse certificates, and enforcement of maximum response times.

One aspiration borrowed from abroad: formal representation of patient associations on official and unofficial commissions. The LPCC already has seats on several committees at the IPO do Porto, but Veloso believes this should be generalized across the country to ensure patient voices shape policy directly.

As cancer incidence climbs and treatment costs rise, the gap between what the state provides and what families need continues to widen. The LPCC's 85-year track record demonstrates resilience and adaptability, but the organization's leaders are clear: without systemic reform in screening access, financial protection, and health literacy, Portugal will continue to diagnose cancers too late — and at too high a cost.